Professor Michael Barry:

From our perspective, we would say that is the way the HSE should be using our recommendations, namely, to try and get the best value for money that it can. Where we would say "No" initially to the initial price ask, as Mr. Flanagan was saying, one can get a substantial price reductions. That means of course that the expenditure from the HSE on that drug is much less and it is therefore available for other things. I think they use our work in a pretty good way many times.